tradingkey.logo
搜索

Liminatus Pharma Ord Shs Class A

LIMN
添加自选
2.990USD
+0.220+7.94%
收盘 11-13 16:00(美东)
4.01M总市值
亏损市盈率 TTM

关于 Liminatus Pharma Ord Shs Class A 公司

Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.

Liminatus Pharma Ord Shs Class A 简介

公司代码- -
公司名称- -
上市日期- -
CEO- -
员工数量- -
证券类型- -
年结日- -
公司地址- -
城市- -
上市交易所- -
国家- -
邮编- -
电话- -
网址- -
公司代码- -
上市日期- -
CEO- -

Liminatus Pharma Ord Shs Class A公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Nicholas Fernandez
Mr. Nicholas Fernandez
Independent Director
Independent Director
333.00
--
Mr. Nicholas Fernandez
Mr. Nicholas Fernandez
Independent Director
Independent Director
333.00
--
Mr. Nicholas Fernandez
Mr. Nicholas Fernandez
Independent Director
Independent Director
333.00
--
Dr. Eun Sook Lee, M.D., Ph.D.
Dr. Eun Sook Lee, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Byong Chul Yoo, Ph.D.
Dr. Byong Chul Yoo, Ph.D.
Chief Science Officer
Chief Science Officer
--
--
Dr. Beom K. Choi
Dr. Beom K. Choi
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Philip Lemons
Mr. Philip Lemons
Independent Director
Independent Director
--
--
Mr. Richard Baek
Mr. Richard Baek
Independent Director
Independent Director
--
--
Mr. Chris Kim
Mr. Chris Kim
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Philip Lemons
Mr. Philip Lemons
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Nicholas Fernandez
Mr. Nicholas Fernandez
Independent Director
Independent Director
333.00
--
Mr. Nicholas Fernandez
Mr. Nicholas Fernandez
Independent Director
Independent Director
333.00
--
Mr. Nicholas Fernandez
Mr. Nicholas Fernandez
Independent Director
Independent Director
333.00
--
Dr. Eun Sook Lee, M.D., Ph.D.
Dr. Eun Sook Lee, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Byong Chul Yoo, Ph.D.
Dr. Byong Chul Yoo, Ph.D.
Chief Science Officer
Chief Science Officer
--
--
Dr. Beom K. Choi
Dr. Beom K. Choi
Chief Technology Officer
Chief Technology Officer
--
--

常见问题

Liminatus Pharma Ord Shs Class A的前五大股东是谁?

Liminatus Pharma Ord Shs Class A 的前五大股东如下:Mr. Nicholas Fernandez
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有